Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Current Assets (2016 - 2025)

Moleculin Biotech's Current Assets history spans 10 years, with the latest figure at $9.7 million for Q4 2025.

  • Quarterly results put Current Assets at $9.7 million for Q4 2025, up 86.48% from a year ago — trailing twelve months through Dec 2025 was $9.7 million (up 86.48% YoY), and the annual figure for FY2025 was $9.7 million, up 86.48%.
  • Current Assets for Q4 2025 was $9.7 million at Moleculin Biotech, up from $7.9 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $88.0 million in Q1 2021 to a low of $5.2 million in Q4 2024.
  • The 5-year median for Current Assets is $31.5 million (2023), against an average of $38.1 million.
  • The sharpest move saw Current Assets surged 538.42% in 2021, then tumbled 80.23% in 2024.
  • Year by year, Current Assets stood at $72.5 million in 2021, then plummeted by 37.11% to $45.6 million in 2022, then crashed by 42.38% to $26.3 million in 2023, then tumbled by 80.23% to $5.2 million in 2024, then skyrocketed by 86.48% to $9.7 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $9.7 million, $7.9 million, and $9.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.